Latest News about BMY
Recent news which mentions BMY
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
November 04, 2024
From Benzinga
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
November 01, 2024
From Benzinga
Stocks Tumble, Nasdaq 100 Selloffs As Tech Giants Disappoint, Crypto Companies Plummet: What's Driving Markets Thursday?
October 31, 2024
From Benzinga
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
October 31, 2024
Tickers
BMY
From Motley Fool
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
October 31, 2024
From Benzinga
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
From Benzinga
From Benzinga
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
October 23, 2024
Tickers
BMY
From Benzinga
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
October 23, 2024
From Benzinga
Why Is Evotec Stock Gaining Today?
October 23, 2024
From Benzinga
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
October 17, 2024
From Benzinga
From Motley Fool
From Benzinga
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
October 07, 2024
From Benzinga
10 Health Care Stocks Whale Activity In Today's Session
October 07, 2024
From Benzinga
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
October 07, 2024
From Benzinga
From Benzinga
Bristol Myers' $10B Cancer Drug Opdivo Scores Expanded Use FDA Approval For Lung Cancer In Pre And Post-Surgery Setting
October 04, 2024
From Benzinga
2 Passive-Income Stocks to Load Up On in October
October 03, 2024
From Motley Fool
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
October 01, 2024
From Benzinga
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
September 30, 2024
From Motley Fool
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
September 30, 2024
From Benzinga
3 Surprisingly Underrated Stocks to Buy Right Now
September 28, 2024
From Motley Fool
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
September 27, 2024
From Benzinga
14 Stocks Gain Momentum As August Inflation Comes In Below Expectations
September 27, 2024
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.